Targeting the androgen receptor with steroid conjugates

Paul M. Levine, Michael J. Garabedian, Kent Kirshenbaum

Research output: Contribution to journalArticle

Abstract

The androgen receptor (AR) is a major therapeutic target in prostate cancer pharmacology. Progression of prostate cancer has been linked to elevated expression of AR in malignant tissue, suggesting that AR plays a central role in prostate cancer cell biology. Potent therapeutic agents can be precisely crafted to specifically target AR, potentially averting systemic toxicities associated with nonspecific chemotherapies. In this review, we describe various strategies to generate steroid conjugates that can selectively engage AR with high potency. Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated. Particular focus is placed on potential applications in AR pharmacology. The review culminates with a description of future prospects for targeting AR.

Original languageEnglish (US)
Pages (from-to)8224-8237
Number of pages14
JournalJournal of Medicinal Chemistry
Volume57
Issue number20
DOIs
StatePublished - Oct 23 2014

Fingerprint

Androgen Receptors
Steroids
Prostatic Neoplasms
Pharmacology
Cell Biology
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Cite this

Targeting the androgen receptor with steroid conjugates. / Levine, Paul M.; Garabedian, Michael J.; Kirshenbaum, Kent.

In: Journal of Medicinal Chemistry, Vol. 57, No. 20, 23.10.2014, p. 8224-8237.

Research output: Contribution to journalArticle

Levine, Paul M. ; Garabedian, Michael J. ; Kirshenbaum, Kent. / Targeting the androgen receptor with steroid conjugates. In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 20. pp. 8224-8237.
@article{7c5754d93a0749adb22f276c97fdc458,
title = "Targeting the androgen receptor with steroid conjugates",
abstract = "The androgen receptor (AR) is a major therapeutic target in prostate cancer pharmacology. Progression of prostate cancer has been linked to elevated expression of AR in malignant tissue, suggesting that AR plays a central role in prostate cancer cell biology. Potent therapeutic agents can be precisely crafted to specifically target AR, potentially averting systemic toxicities associated with nonspecific chemotherapies. In this review, we describe various strategies to generate steroid conjugates that can selectively engage AR with high potency. Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated. Particular focus is placed on potential applications in AR pharmacology. The review culminates with a description of future prospects for targeting AR.",
author = "Levine, {Paul M.} and Garabedian, {Michael J.} and Kent Kirshenbaum",
year = "2014",
month = "10",
day = "23",
doi = "10.1021/jm500101h",
language = "English (US)",
volume = "57",
pages = "8224--8237",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - Targeting the androgen receptor with steroid conjugates

AU - Levine, Paul M.

AU - Garabedian, Michael J.

AU - Kirshenbaum, Kent

PY - 2014/10/23

Y1 - 2014/10/23

N2 - The androgen receptor (AR) is a major therapeutic target in prostate cancer pharmacology. Progression of prostate cancer has been linked to elevated expression of AR in malignant tissue, suggesting that AR plays a central role in prostate cancer cell biology. Potent therapeutic agents can be precisely crafted to specifically target AR, potentially averting systemic toxicities associated with nonspecific chemotherapies. In this review, we describe various strategies to generate steroid conjugates that can selectively engage AR with high potency. Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated. Particular focus is placed on potential applications in AR pharmacology. The review culminates with a description of future prospects for targeting AR.

AB - The androgen receptor (AR) is a major therapeutic target in prostate cancer pharmacology. Progression of prostate cancer has been linked to elevated expression of AR in malignant tissue, suggesting that AR plays a central role in prostate cancer cell biology. Potent therapeutic agents can be precisely crafted to specifically target AR, potentially averting systemic toxicities associated with nonspecific chemotherapies. In this review, we describe various strategies to generate steroid conjugates that can selectively engage AR with high potency. Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated. Particular focus is placed on potential applications in AR pharmacology. The review culminates with a description of future prospects for targeting AR.

UR - http://www.scopus.com/inward/record.url?scp=84908375071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908375071&partnerID=8YFLogxK

U2 - 10.1021/jm500101h

DO - 10.1021/jm500101h

M3 - Article

C2 - 24936953

AN - SCOPUS:84908375071

VL - 57

SP - 8224

EP - 8237

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 20

ER -